PINDOLOL Drug Interactions
Also known as: Pindolol
Pindolol is a type of medicine called a beta-blocker, used to treat high blood pressure (hypertension). It works by helping to relax blood vessels and slow the heart rate, making it easier for your heart to pump blood. This helps to lower your blood pressure and reduce the strain on your heart.PINDOLOL has 7 documented drug interactions in our database, including 0 contraindicated, 1 major, 4 moderate, and 2 minor interactions.
0
Contraindicated
1
Major
4
Moderate
2
Minor
The co-administration of paroxetine, a potent CYP2D6 inhibitor, with pindolol, a beta-blocker primarily metabolized by CYP2D6, can significantly increase pindolol plasma concentrations. This elevated exposure to pindolol may lead to enhanced beta-blockade effects, including severe bradycardia, hypotension, and heart block, particularly in susceptible patients.
Mechanism
Paroxetine potently inhibits the cytochrome P450 2D6 (CYP2D6) enzyme. Pindolol is primarily metabolized by CYP2D6, therefore, paroxetine reduces the metabolism and clearance of pindolol, leading to increased systemic exposure and pharmacodynamic effects.
Clinical Management
This combination should generally be avoided. If co-administration is unavoidable, a significant reduction in pindolol dosage (e.g., by 50% or more) is recommended, along with close and frequent monitoring of heart rate, blood pressure, and ECG for signs of excessive beta-blockade. Consider using an alternative beta-blocker that is not primarily metabolized by CYP2D6 (e.g., atenolol, nadolol, bisoprolol) or an antidepressant with minimal CYP2D6 inhibition (e.g., sertraline, escitalopram).
Fluoxetine can increase pindolol plasma levels, potentially leading to enhanced beta-blockade effects such as bradycardia, hypotension, and heart block. This interaction is due to fluoxetine's potent inhibition of CYP2D6, an enzyme involved in pindolol metabolism.
Mechanism
Fluoxetine is a potent inhibitor of cytochrome P450 2D6 (CYP2D6). Pindolol is partially metabolized by CYP2D6, so fluoxetine can decrease its metabolism and increase its systemic exposure.
Clinical Management
Monitor patients closely for signs of increased beta-blockade, including bradycardia, hypotension, and dizziness, especially when initiating or discontinuing fluoxetine or changing its dose. Consider a dose reduction of pindolol or using an alternative antidepressant with less CYP2D6 inhibitory potential, such as sertraline or escitalopram, if close monitoring is not feasible.
The combination of pindolol and citalopram may lead to an increased risk of bradycardia and hypotension due to additive pharmacodynamic effects. While citalopram is not a strong CYP2D6 inhibitor, pindolol is metabolized by CYP2D6, so a pharmacokinetic interaction is possible, though less pronounced than with other SSRIs.
Mechanism
Both pindolol (a beta-blocker) and citalopram (an SSRI) can independently cause bradycardia, leading to an additive pharmacodynamic effect. Additionally, pindolol is metabolized by CYP2D6, and citalopram is a weak inhibitor of CYP2D6, which could potentially increase pindolol plasma concentrations.
Clinical Management
Monitor patients closely for signs and symptoms of bradycardia, hypotension, and other beta-blocker-related adverse effects, especially when initiating or adjusting doses of either medication. Consider using the lowest effective doses of both drugs. If adverse effects occur, dose reduction or switching to an alternative antidepressant with minimal CYP2D6 inhibition (e.g., sertraline, escitalopram) or a beta-blocker primarily cleared renally (e.g., atenolol, nadolol) may be necessary.
Fluoxetine, a potent CYP2D6 inhibitor, can increase plasma concentrations of pindolol, which is partially metabolized by CYP2D6. This interaction may lead to enhanced beta-blockade effects, potentially causing bradycardia, hypotension, or heart block.
Mechanism
Fluoxetine inhibits the cytochrome P450 2D6 (CYP2D6) enzyme, which is involved in the metabolism of pindolol. This inhibition reduces pindolol clearance, leading to increased systemic exposure and enhanced pharmacodynamic effects.
Clinical Management
Monitor patients closely for signs of enhanced beta-blockade, including bradycardia, hypotension, and dizziness, especially when initiating or adjusting fluoxetine. Consider using a beta-blocker less dependent on CYP2D6 metabolism (e.g., atenolol, bisoprolol, nadolol) or an antidepressant with less CYP2D6 inhibition (e.g., sertraline, escitalopram) if close monitoring is not feasible or if adverse effects occur.
Coadministration of fluvoxamine and pindolol can increase pindolol plasma concentrations, potentially leading to enhanced beta-blockade effects such as bradycardia, hypotension, or heart block. This interaction is primarily due to fluvoxamine's inhibition of CYP1A2, which is involved in pindolol's metabolism.
Mechanism
Fluvoxamine is a potent inhibitor of cytochrome P450 1A2 (CYP1A2). Pindolol is metabolized, in part, by CYP1A2, thus fluvoxamine can decrease the metabolism and increase the plasma levels of pindolol.
Clinical Management
Monitor patients closely for signs and symptoms of increased beta-blockade, including bradycardia, hypotension, and dizziness. A reduction in pindolol dosage may be necessary if adverse effects occur, or consider alternative antidepressants with less CYP1A2 inhibitory potential.
The interaction between pindolol and sertraline is generally considered minor. Sertraline has minimal CYP2D6 inhibitory effects, which is the primary metabolic pathway for some beta-blockers, but pindolol is not extensively metabolized by CYP2D6. Both drugs can independently cause bradycardia, but additive effects are unlikely to be clinically significant with typical doses.
Mechanism
Sertraline is a weak inhibitor of CYP2D6. While some beta-blockers are extensively metabolized by CYP2D6, pindolol is primarily metabolized by CYP2D9 and to a lesser extent CYP2D6, with significant renal excretion of unchanged drug. Therefore, sertraline's weak CYP2D6 inhibition is unlikely to significantly alter pindolol plasma concentrations.
Clinical Management
No specific dose adjustments are usually required for pindolol or sertraline when co-administered. Monitor patients for signs of excessive beta-blockade (e.g., bradycardia, hypotension), especially if they are sensitive to beta-blockers or have underlying cardiac conditions. If concerns arise, consider alternative SSRIs with even lower CYP2D6 inhibition potential.
The interaction between pindolol and escitalopram is generally considered to be of minor clinical significance. Escitalopram has minimal CYP2D6 inhibition, which is the primary metabolic pathway for some beta-blockers, thus significantly elevated pindolol levels are unlikely. However, both drugs can independently cause bradycardia, so an additive pharmacodynamic effect is theoretically possible.
Mechanism
Pindolol is metabolized primarily by CYP2D6. Escitalopram is a weak inhibitor of CYP2D6, therefore, clinically significant pharmacokinetic inhibition of pindolol metabolism is not expected. Both drugs can exert bradycardic effects, leading to a potential, though unlikely, additive pharmacodynamic effect.
Clinical Management
No specific dose adjustments are typically required. Monitor patients for signs of excessive beta-blockade, such as bradycardia, hypotension, or dizziness, especially during initiation or dose changes of either medication. If symptoms occur, consider dose reduction of pindolol or alternative agents.
For complete prescribing information:
View full PINDOLOL monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.